Interstitial Cystitis Drugs Global Market Report 2024

The interstitial cystitis drugs market size has grown strongly in recent years. It will grow from $1.28 billion in 2023 to $1.36 billion in 2024 at a compound annual growth rate (CAGR) of 6.5%. The growth observed in the historical period can be ascribed to several factors, including heightened awareness of diseases, advancements in diagnostic techniques, increased investments from the pharmaceutical industry, a rise in healthcare spending, collaborative research endeavors, and the presence of patient advocacy and support groups.

The interstitial cystitis drugs market size is expected to see strong growth in the next few years. It will grow to $1.67 billion in 2028 at a compound annual growth rate (CAGR) of 5.3%. The anticipated growth in the forecast period is linked to several factors, including a heightened focus on rare diseases, the expansion of biopharmaceutical innovation, regulatory backing for orphan drugs, a growing global disease burden, the adoption of patient-centric healthcare approaches, and ongoing collaborative research initiatives. Noteworthy trends expected in the forecast period encompass progress in diagnostic techniques, the emergence of targeted therapies, the promotion of patient-centric approaches, collaborative research initiatives, advancements in surgical interventions, and the development of biomarkers.

The anticipated increase in chronic diseases is poised to drive the expansion of the interstitial cystitis drug market in the future. Chronic diseases denote enduring health conditions persisting over an extended period, often throughout an individual's lifetime. Drugs for cystitis target and eliminate bacteria causing urinary tract infections, addressing symptoms such as painful urination, frequent urination, and urgency linked to chronic diseases such as urinary tract infections (UTIs). Notably, in January 2023, the National Institute of Health, a US-based public health research agency, reported that urinary tract infections accounted for over 1 million emergency department visits in the US, ranking as the seventh most common reason for such visits. Among these cases, 22% (220,000) were considered complicated UTIs, leading to approximately 100,000 hospital admissions annually. Consequently, the increasing incidence of chronic diseases propels the growth of the interstitial cystitis drug market.

The surging demand for personalized medicine is anticipated to fuel the advancement of the interstitial cystitis drug market. Personalized medicine represents an innovative medical treatment approach considering individual differences in genes, environments, and lifestyles. This approach enhances the efficacy of interstitial cystitis drugs by tailoring treatments to individual patient characteristics, optimizing therapeutic outcomes, and minimizing adverse effects, thereby improving the overall management of interstitial cystitis. For example, in 2022, the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs). Among the 35 therapeutic NMEs, approximately 34% (12 of them) are classified as personalized medicines by the Personalized Medicine Coalition (PMC). Hence, the increasing demand for personalized medicine propels the growth of the interstitial cystitis drug market.

The growth of the interstitial cystitis drugs market is expected to be hampered by restricted research and development efforts. Insufficient research activities can impede the progress of new treatment options and the comprehension of interstitial cystitis. For instance, as of March 2023, the American Medical Association, a professional association and advocacy group for physicians and medical students in the United States, reported that health spending in the country saw a 2.7% increase in 2021, reaching $4.3 trillion, or $12,914 per capita. This figure is notably lower than the 10.3% increase observed in 2020. Consequently, the limited scope of research and development activities is acting as a constraint on the expansion of the interstitial cystitis drugs market.

Leading companies in the interstitial cystitis drugs market are increasingly concentrating on the development of novel treatment options to gain a competitive advantage. These options encompass drugs used for treating a specific disease, including both established treatments and experimental options undergoing clinical trials. For example, in April 2021, Kyorin Pharmaceutical Co. Ltd., a pharmaceutical company based in Japan, introduced Zymso Intravesical Solution 50%, a fresh treatment alternative for interstitial cystitis. This intravenous infusion, containing 50% (w/w) dimethyl sulfoxide, effectively alleviates interstitial cystitis symptoms. Zymso's introduction followed the successful results of a phase III clinical trial conducted in Japan, demonstrating its efficacy in symptom improvement for interstitial cystitis. The trial involved 96 interstitial cystitis patients randomly assigned to receive either Zymso or a placebo. After six weeks of treatment, patients receiving Zymso exhibited significant symptom improvement compared to those receiving the placebo. This launch is crucial for addressing interstitial cystitis and is anticipated to provide relief to individuals grappling with this persistent condition.

In August 2021, Imbrium Therapeutics L.P., a US-based biotechnology company, acquired the rights to develop and commercialize IMB-150 from PureTech Health for $6 million. IMB-150, a non-opioid treatment for interstitial cystitis, is being developed using PureTech's Alivio technology platform. This acquisition is poised to assist Imbrium Therapeutics L.P. in diversifying its product portfolio with non-opioid treatments, including a validated preclinical model for interstitial cystitis treatment. PureTech Health, also a US-based biotechnology company, focuses on discovering, developing, and commercializing drugs for various diseases, including interstitial cystitis.

Major companies operating in the interstitial cystitis drugs market report are Pfizer Inc., Johnson & Johnson , Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, UCB S.A., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Cipla Limited, Ferring B.V., Grunenthal Pharma, Kyorin Pharmaceutical Co. Ltd., Seikagaku Corporation, UroGen Pharma, Alivio Therapeutics, Imbrium Therapeutics, Urigen Pharmaceuticals, Lipella Pharmaceuticals, GlycoMira Therapeutics Inc..

North America was the largest region in the interstitial cystitis drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interstitial cystitis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the interstitial cystitis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Interstitial cystitis drugs are medications designed to alleviate the symptoms of interstitial cystitis, a persistent inflammation of the bladder leading to frequent and painful urination. This condition arises from bladder inflammation, disruption of the protective bladder lining, and potential influences from genetics, autoimmune reactions, and environmental triggers.

The primary categories of interstitial cystitis drugs encompass pentosan polysulfate sodium, dimethyl sulfoxide, and other options. Pentosan polysulfate sodium is a synthetic medication serving as a mucosal protector with anti-inflammatory properties. Treatment modalities include oral and intravesical therapy, available through various distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The interstitial cystitis drugs market research report is one of a series of new reports that provides interstitial cystitis drugs market statistics, including interstitial cystitis drugs industry global market size, regional shares, competitors with a interstitial cystitis drugs market share, detailed interstitial cystitis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the interstitial cystitis drugs industry. This interstitial cystitis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The interstitial cystitis drugs market consists of revenues earned by entities by providing physical therapy, topical medications and immunomodulators. The market value includes the value of related goods sold by the service provider or included within the service offering. The interstitial cystitis drugs market also includes of sales of analgesics, pain relievers, oral supplements, and bladder kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.